465 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 130 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| GYC | 93 | 99.73% | View COA → |
| Zlz Peptide | 93 | 99.72% | View COA → |
| Qingdao Sigma Chemical | 73 | 99.63% | View COA → |
Recent certificates: #16760 (99.707%) · #16762 (99.853%) · #23587 (99.689%) · #22208 (99.9%) · #22209 (99.9%) · #22296 (99.9%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
This case report highlights a rare but severe adverse event associated with tirzepatide, suggesting that clinicians should be vigilant for interstitial nephritis in patients experiencing unexplained renal decline whil…
The development of GZR18 represents a significant step towards addressing the unmet need for more convenient and effective long-term weight management solutions. The potential for a less frequent dosing regimen (every…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This study highlights the critical importance of timing when discontinuing GLP-1RA/tirzepatide before pregnancy to mitigate gestational diabetes risk. While longer discontinuation periods appear safe, abrupt cessation…
This case report highlights a critical potential adverse effect of GLP-1 RAs on mood and behavior, particularly in vulnerable populations such as those with pre-existing Major Depressive Disorder. Given that GLP-1 rec…
This trial is crucial because it seeks to provide a much-needed treatment option for obesity in individuals with Type 1 Diabetes, a population with limited pharmacological interventions. A successful outcome could sig…
The potential for a therapeutic strategy that not only achieves significant weight loss but also preserves crucial muscle mass and bone health would be a major advancement in obesity management. Current weight loss ap…
This comparative review is crucial for clinicians and patients in making informed treatment decisions, highlighting the distinct strengths of each medication. The findings underscore Tirzepatide's potent efficacy in w…
This real-world data underscores the substantial weight-loss benefits of GLP-1 RAs, particularly tirzepatide, in patients with rheumatic and musculoskeletal diseases, a population often challenged by weight management…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
This comprehensive "Evidence Map" highlights the transformative potential of incretin-based anti-obesity medications as a crucial therapeutic strategy for women suffering from PCOS and obesity. By consolidating existi…
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
This case highlights the critical importance of vigilant monitoring of thyroid function in post-thyroidectomy patients initiating tirzepatide or similar incretin-based medications. The significant weight loss and pote…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
This study provides compelling evidence that tirzepatide not only reduces overall body weight but also dramatically improves a crucial marker of metabolic health: WHtR. Achieving a healthy WHtR is strongly associated …
This study provides important reassurance regarding the cardiovascular safety profile of tirzepatide in a high-risk population. Given tirzepatide's superior efficacy in glycemic control and weight reduction, demonstra…
This study provides reassuring short-term data regarding tirzepatide and calcitonin levels, suggesting that while a slight increase may occur, it generally remains within a safe range for adults with obesity. This fin…
This review underscores the transformative potential of novel antiobesity medications in improving cardiovascular health outcomes for obese patients. The demonstrated 20% reduction in MACE by semaglutide sets a new be…
This comprehensive review underscores the critical role of the gut microbiome as a mediator of GLP-1 therapy effects on liver health, particularly in patients with Type 2 Diabetes Mellitus. Understanding these mechani…
This real-world data strongly supports the efficacy of tirzepatide in managing metabolic syndrome, especially when combined with lifestyle interventions. The substantial weight loss and significant improvements in met…
The findings from this study are highly significant for patients managing type 2 diabetes and obesity with Tirzepatide. Knowing that injection site (upper arm, thigh, or abdomen) does not significantly impact drug abs…
This research represents a significant step towards personalized medicine in the treatment of obesity and type 2 diabetes. By understanding the genetic underpinnings of GLP-1 RA response, clinicians could potentially …
This case report is significant as it highlights a previously unreported dermatological adverse event associated with tirzepatide use. Clinicians prescribing tirzepatide should be aware of SDRIFE as a potential, albei…
This comprehensive analysis strengthens the evidence for Tirzepatide's potential as a multi-organ protective agent, extending its utility beyond metabolic control. The findings suggest that Tirzepatide could be a valu…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…
This study highlights the critical importance of long-term management strategies for obesity and overweight, even after successful initial weight loss with potent agents like tirzepatide. The significant weight regain…
This finding suggests that initiating Tirzepatide in patients with type 2 diabetes who are new to GLP-1 receptor agonists may offer a distinct and superior advantage in improving liver health, specifically regarding f…
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
This study highlights tirzepatide's profound potential as an effective add-on therapy for Type 2 Diabetes patients whose blood sugar remains poorly controlled despite existing insulin and metformin regimens. The dual …
This study is highly significant because it could establish Tirzepatide as more than just a powerful glucose-lowering agent, potentially offering a crucial benefit in addressing diabetes-related cognitive impairment. …
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
Given the significant public health burden of Cannabis Use Disorder and the scarcity of effective pharmacological interventions, a successful outcome from this trial could be transformative. Tirzepatide, a dual GLP-1 …
This study provides crucial evidence suggesting that Tirzepatide offers superior weight loss efficacy compared to oral semaglutide, which can significantly inform clinical decision-making for managing overweight and o…
Free, no account — handy when you're working with Tirzepatide.